IFNA1 and incontinentia pigmenti: Although IP is a well-known adverse effect of IFN treatments for hepatitis C patients, and sometimes leads to death [20], it occurs at a rate of only 0.3 % among Japanese patients treated with IFN monotherapy or combined RBV therapy [10, 12] and in only 0.01 % of patients in other countries [21].